329 related articles for article (PubMed ID: 9808693)
1. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist.
Ligneau X; Lin J; Vanni-Mercier G; Jouvet M; Muir JL; Ganellin CR; Stark H; Elz S; Schunack W; Schwartz J
J Pharmacol Exp Ther; 1998 Nov; 287(2):658-66. PubMed ID: 9808693
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
McLeod RL; Rizzo CA; West RE; Aslanian R; McCormick K; Bryant M; Hsieh Y; Korfmacher W; Mingo GG; Varty L; Williams SM; Shih NY; Egan RW; Hey JA
J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
4. [125I]iodoproxyfan and related compounds: a reversible radioligand and novel classes of antagonists with high affinity and selectivity for the histamine H3 receptor.
Stark H; Purand K; Hüls A; Ligneau X; Garbarg M; Schwartz JC; Schunack W
J Med Chem; 1996 Mar; 39(6):1220-6. PubMed ID: 8632428
[TBL] [Abstract][Full Text] [Related]
5. [125I]iodoproxyfan, a new antagonist to label and visualize cerebral histamine H3 receptors.
Ligneau X; Garbarg M; Vizuete ML; Diaz J; Purand K; Stark H; Schunack W; Schwartz JC
J Pharmacol Exp Ther; 1994 Oct; 271(1):452-9. PubMed ID: 7965746
[TBL] [Abstract][Full Text] [Related]
6. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
Stark H; Hüls A; Ligneau X; Arrang JM; Schwartz JC; Schunack W
Pharmazie; 1997 Jul; 52(7):495-500. PubMed ID: 9266588
[TBL] [Abstract][Full Text] [Related]
7. A novel series of (phenoxyalkyl)imidazoles as potent H3-receptor histamine antagonists.
Ganellin CR; Fkyerat A; Bang-Andersen B; Athmani S; Tertiuk W; Garbarg M; Ligneau X; Schwartz JC
J Med Chem; 1996 Sep; 39(19):3806-13. PubMed ID: 8809168
[TBL] [Abstract][Full Text] [Related]
8. Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971.
Hey JA; Aslanian R; Bolser DC; Chapman RW; Egan RW; Rizzo CA; Shih NY; Fernandez X; McLeod RL; West R; Kreutner W
Arzneimittelforschung; 1998 Sep; 48(9):881-8. PubMed ID: 9793613
[TBL] [Abstract][Full Text] [Related]
9. Development of chiral N-alkylcarbamates as new leads for potent and selective H3-receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo activity.
Sasse A; Kiec-Kononowicz K; Stark H; Motyl M; Reidemeister S; Ganellin CR; Ligneau X; Schwartz JC; Schunack W
J Med Chem; 1999 Feb; 42(4):593-600. PubMed ID: 10052966
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
[TBL] [Abstract][Full Text] [Related]
11. H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles.
Mor M; Bordi F; Silva C; Rivara S; Crivori P; Plazzi PV; Ballabeni V; Caretta A; Barocelli E; Impicciatore M; Carrupt PA; Testa B
J Med Chem; 1997 Aug; 40(16):2571-8. PubMed ID: 9258364
[TBL] [Abstract][Full Text] [Related]
12. Changes in histamine H3 receptor responsiveness in mouse brain.
Morisset S; Traiffort E; Arrang JM; Schwartz JC
J Neurochem; 2000 Jan; 74(1):339-46. PubMed ID: 10617138
[TBL] [Abstract][Full Text] [Related]
13. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
Esbenshade TA; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Fox GB; Faghih R; Bennani YL; Williams M; Hancock AA
J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603
[TBL] [Abstract][Full Text] [Related]
14. 4-Alkynylphenyl imidazolylpropyl ethers as selective histamine H3-receptor antagonists with high oral central nervous system activity.
Krause M; Ligneau X; Stark H; Garbarg M; Schwartz JC; Schunack W
J Med Chem; 1998 Oct; 41(21):4171-6. PubMed ID: 9767653
[TBL] [Abstract][Full Text] [Related]
15. Substituted N-phenylcarbamates as histamine H3 receptor antagonists with improved in vivo potency.
Reidemeister S; Stark H; Ligneau X; Ganellin CR; Schwartz JC; Schunack W
Pharmazie; 2000 Feb; 55(2):83-6. PubMed ID: 10723763
[TBL] [Abstract][Full Text] [Related]
16. S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist.
Garbarg M; Arrang JM; Rouleau A; Ligneau X; Tuong MD; Schwartz JC; Ganellin CR
J Pharmacol Exp Ther; 1992 Oct; 263(1):304-10. PubMed ID: 1383495
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of GT-2016, a non-thiourea-containing histamine H3 receptor antagonist: in vitro and in vivo studies.
Tedford CE; Yates SL; Pawlowski GP; Nalwalk JW; Hough LB; Khan MA; Phillips JG; Durant GJ; Frederickson RC
J Pharmacol Exp Ther; 1995 Nov; 275(2):598-604. PubMed ID: 7473144
[TBL] [Abstract][Full Text] [Related]
18. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
[TBL] [Abstract][Full Text] [Related]
19. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology.
Ligneau X; Perrin D; Landais L; Camelin JC; Calmels TP; Berrebi-Bertrand I; Lecomte JM; Parmentier R; Anaclet C; Lin JS; Bertaina-Anglade V; la Rochelle CD; d'Aniello F; Rouleau A; Gbahou F; Arrang JM; Ganellin CR; Stark H; Schunack W; Schwartz JC
J Pharmacol Exp Ther; 2007 Jan; 320(1):365-75. PubMed ID: 17005916
[TBL] [Abstract][Full Text] [Related]
20. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.
Tedford CE; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Handley MK; Yates SL
J Pharmacol Exp Ther; 1999 May; 289(2):1160-8. PubMed ID: 10215700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]